Additional data, from an amyloid and tau mouse model of AD (3x‐Tg‐fAD mice) treated with intranasal insulin for 2 months, demonstrated improved memory (in novel object recognition task and MWM), reduced depression‐like behaviour (via tail suspension and forced swim tests) and decreased hyperphosphorylated tau, Aβ oligomers and 3‐nitrotyrosine in the frontal cortex and hippocampus (Barone et al., 2019). Here, MAPT is linked to Alzheimer disease.